@misc{oai:repo.qst.go.jp:00069127,
 author = {Katou, Hirotoshi and Yamada, Shigeru and Yasuda, Shigeo and Maeda, Yukiteru and Kamada, Tadashi and Mizoe, Junetsu and Ootou, Masao and Tsujii, Hirohiko and 加藤 博敏 and 山田 滋 and 安田 茂雄 and 前田 幸輝 and 鎌田 正 and 溝江 純悦 and 大藤 正雄 and 辻井 博彦},
 month = {Oct},
 note = {Introduction: A phase II study of Carbon Ion Radiotherapy (CIRT) for HCC according to a 52.8 cobalt gray equivalent (GyE) /4-fraction/1-week regime was conducted from April 2001 to February 2003. Purpose: To evaluate the efficacy of 4-fraction CIRT for HCC. Methods: Eligibility criteria were as follows: biopsy-proven, recurrent or residual tumor after other treatments or no indication for any other treatment; no prior radiotherapy for target tumors; Child-Pugh grade A or B. Results: Forty-seven patients with chronic liver disease of Child-Pugh grade A in 37, B in 10 were enrolled. The median age at therapy was 69 years. The median tumor size was 3.7 (1.2-7.5)cm in diameter. During a median follow-up of 60 (48-70)months, no treatment-related hepatic failure and death occurred. Incidence of grade 3 early hepatic toxicity in the serum-GPT, ALB, T.BIL, PT and ALP according to NCI-CTC (ver.2) was 0, 11, 0, 2, and 13%, respectively. No other grade 3 or worse adverse effect occurred. In 92% of patients, the Child-Pugh score did not increase by more than 1 point within 1 year after the therapy. Local control rate was 96% at 1 to 5 years. Overall and cause-specific survival rates at 3 and 5 years were 57% and 67%, 34% and 42%, respectively. Those in the 27 patients initially treated with CIRT were 63% and 81%, 40% and 52%, respectively. Conclusion: Four-fraction CIRT for HCC seems to have a promising potential as a new, radical, and minimally invasive therapeutic option for HCC., ILCA's First Annual Conference},
 title = {Phase II Study of 4-fraction Carbon Ion Radiotherapy for Hepatocellular Carcinoma},
 year = {2007}
}